araag2/HINT huggingface dataset:
Clinical trial NCT00421551 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: darunavir, ritonavir
SMILES: [H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed HIV-1 infection.

          -  Documented level of HIV-1 RNA at initiation of antiretroviral treatments

          -  Prior antiretroviral regimen, including at least 2 NRTIs combined to 1 PI or NNRTI or
             a third NRTI for at least 18 months prior to study entry.

          -  CD4 count of 200 cells per mm3 or greater.

          -  Viral load below 400 copies per ml within 18 months prior to entry and below 50 copies
             per mL at entry.

          -  Willing to use acceptable methods of contraception

        Exclusion Criteria:

          -  Previous virological failure under prior PI-based regimen.

          -  Prior therapy in the darunavir.

          -  HIV-2 infected patients.

          -  Absence of documented level of HIV-1 RNA at initiation of antiretroviral treatments

          -  Hepatitis B or C infection within 90 days prior to study entry.

          -  Therapies including interferon, interleukin-2, cytotoxic chemotherapy or
             immunosuppressors at study entry.

          -  Serious acute illness requiring systemic treatment or hospitalization in the 14 days
             prior to study entry.

          -  Treatment for an active AIDS defining opportunistic infection within 30 days prior to
             screening

          -  Drug or alcohol use or any dependence that would interfere with compliance.

          -  Pregnancy or breastfeeding
Clinical trial NCT01068600 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol, placebo to indacaterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:

               1. Smoking history of at least 10 pack-years

               2. Post-bronchodilator FEV1 <80% and ≥30% of the predicted normal value

               3. Post-bronchodilator FEV1/FVC (forced vital capacity) <70%

        Exclusion Criteria:

          -  Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or
             antibiotics and/or hospitalization for in the 6 weeks prior to screening

          -  Patients who have had a respiratory tract infection within 6 weeks prior to screening

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular comorbid conditions

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00694304 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: vortioxetine (lu aa21004)
SMILES: CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

        - Patients who completed 8-week short-term treatment study for Major Depressive Episode,
        NCT00635219 / 11984A

        Exclusion Criteria:

          -  Any current psychiatric disorder other than MDD as defined in the Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Ed., Text revision (DSM-IV TR)

          -  Female patients of childbearing potential who are not using effective contraception

          -  Use of any psychoactive medication

        Other protocol-defined inclusion and exclusion criteria may apply.
Clinical trial NCT01211834 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tocilizumab, dmards, placebo, dmards
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >= 18 years of age

          -  Active RA of > 6monts duration

          -  Received permitted DMARDs each at a stable dose for at least 8 weeks

        Exclusion Criteria:

          -  Rheumatic autoimmune disease other than RA

          -  Significant systemic involvement secondary to RA

          -  ALT or AST > ULNⅹ1.5

          -  Platelet count < 100,000/mm3

          -  Hemoglobin < 8.5 g/dL

          -  White blood cells < 3,000/mm3

          -  Absolute neutrophil count < 2,000/mm3

          -  Absolute lymphocyte count < 500/mm3
Clinical trial NCT00232141 (phase 3, status: completed)
Conditions: hiv infections, peripheral neuropathy
ICD codes: Z21, G90.09
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with confirmed diagnosis of HIV infection

          -  HIV-associated neuropathic pain (nerve pain) for at least 3 months prior to study
             start

          -  subjects with moderate to severe pain

          -  subjects on stable HIV and pain medications (some medications are not allowed to be
             taken while participating in the study).

        Exclusion Criteria:

          -  Pregnant or breast feeding females

          -  subjects using street drugs or alcohol abusers during the study

          -  subject's on anti-diabetic medications

          -  use of neuroregenerative agents or neurotoxic chemotherapeutic agents 3 months prior
             to study start and throughout the study

          -  use of neurotoxic drugs (other than D-drugs) within a month prior to study start and
             throughout the study.
Clinical trial NCT01276639 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cp-690,550, cp-690,550, placebo/cp-690,550, placebo/cp-690,550
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  Are 18 years or older with diagnosis for at least 12 months of moderate to severe
             plaque psoriasis covering as least 10%of body surface area

          -  a Psoriasis Area and Severity Index (PASI) score of 12 and are considered to be
             candidates for systemic or light therapy

          -  No evidence of active or latent tuberculosis

        Exclusion Criteria:

          -  Non-plaque or drug induced forms of psoriasis

          -  cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot
             discontinue phototherapy (PUVA or UVB)

          -  any uncontrolled significant medical condition
Clinical trial NCT01365507 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (diagnosed clinically) for 24 weeks or longer prior to randomisation
             (visit 2)

          -  Insulin naïve subjects (Allowed are: Previous short term insulin treatment no longer
             than or equal to 14 days in total; Treatment during hospitalisation or during
             gestational diabetes is allowed for periods longer than 14 days in total)

          -  Current treatment: Metformin alone or metformin in any combination of 1 or 2
             additional OADs (oral anti-diabetic drug) including an insulin secretagogue
             (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors,
             alpha-glucosidase inhibitors or thiazolidinediones (TZDs) - all with unchanged dosing
             for at least 12 weeks prior to randomisation (visit 2). Metformin dose, alone or in
             combination (including fixed combination), must be at least 1000 mg daily

          -  HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive)

          -  BMI (Body Mass Index) below or equal to 45 kg/m^2

          -  Ability and willingness to adhere to the protocol including self measurement of plasma
             glucose

        Exclusion Criteria:

          -  Treatment with GLP-1 (glucagon like peptide) receptor agonists within the last 12
             weeks prior to randomisation (visit 2)

          -  Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the
             last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial
             physician)

          -  Previous participation in this trial. Participation is defined as randomised.
             Re-screening is allowed once during the recruitment period

          -  Known or suspected hypersensitivity to trial products or related products

          -  The receipt of any investigational drug within 4 weeks prior to randomisation (visit
             2)

          -  Anticipated significant lifestyle changes during the study, e.g. shift work (including
             permanent night/evening shift workers) as well as highly variable eating habits
Clinical trial NCT01177098 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost /timolol formulation a fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has ocular hypertension or glaucoma in both eyes

          -  Requires IOP-lowering therapy in each eye

        Exclusion Criteria:

          -  Active or recurrent eye disease that would interfere with interpretation of study data
             in either eye

          -  History of any eye surgery or laser in either eye within 6 months

          -  Required chronic use of other eye medications during the study

          -  Anticipated wearing of contact lenses during the study.

          -  Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days
Clinical trial NCT00387088 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female

          2. At least 40 years old

          3. Smoker or ex-smoker

          4. Smoking history > 10 pack-years

          5. Forced Expiratory Volume in 1 Second (FEV1) < 60% predicted

        Exclusion Criteria:

          1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or
             hospitalisation for cardiac failure

          2. History of asthma or allergic conditions.

          3. Malignancy requiring treatment within past 5 years

          4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident
             bronchiectasis

          5. Known active tuberculosis

          6. Known hypersensitivity to anticholinergic drugs.
Clinical trial NCT00463606 (phase 3, status: completed)
Conditions: hypercholesterolemia, dyslipidemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: abt-335 and rosuvastatin calcium, abt-335, rosuvastatin calcium
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria

          -  Adult male and female participants who voluntarily sign the informed consent.

          -  Fasting lipid results following greater than 12-hour fasting period:

               -  Triglycerides level greater than or equal to 150 mg/dL,

               -  High-density lipoprotein cholesterol less than 40 mg/dL for males and less than
                  50 mg/dL for females, and

               -  Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL.

          -  Participant must agree to utilize adequate birth control methods and adhere to the
             American Heart Association (AHA) diet.

        Exclusion Criteria

          -  Participants with unstable medical conditions, medical conditions considered
             inappropriate in a clinical trial, or participants who are taking excluded concomitant
             medications are not allowed in the study.

          -  Participants receiving coumarin anticoagulants or systemic cyclosporine.
Clinical trial NCT00212836 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have a documented current diagnosis of schizophrenia of paranoid, disorganized,
             catatonic, residual, or undifferentiated subtype with persistent negative symptoms.

          -  No increase in level of psychiatric care during the past few months due to worsening
             of symptoms of schizophrenia.

          -  Caregiver required.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable clinically significant medical condition.

          -  Have any other psychiatric disorder other than schizophrenia as a primary diagnosis
             including depression.
Clinical trial NCT00471952 (phase 3, status: completed)
Conditions: migraine with aura, migraine without aura
ICD codes: G43.111, G43.011, G43.119, G43.101, G43.001, G43.109, G43.711
Drugs: maxalt 10mg mlt plus caffeine 75mg, maxalt 10mg mlt plus placebo, placebo + placebo
SMILES: CN1C=NC2=C1C(=O)N(C)C(=O)N2C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is 18-65 years of age

          -  Diagnosis of migraine with or without aura

          -  1 year history of migraine with 1-6 migraine attacks per month in the the three months
             prior to screening

          -  Medication for migraine prevention with a stable dose for at least 1 month prior to
             screening

          -  Has successfully treated a migraine attack with a triptan medication

        Exclusion Criteria:

          -  Confirmed or suspected ischemic heart disease

          -  History of congenital heart disease

          -  History of cerebrovascular disease, including stroke

          -  History of ischemic abdominal disease

          -  Uncontrolled hypertension

          -  History of epilepsy

          -  History of basilar or hemiplegic migraine

          -  Impaired hepatic or renal function

          -  Greater than 15 headache days per month

          -  Subjects on an MAOI

          -  Subjects taking and ergotamine, or ergot containing preventive medication

          -  Subject is pregnant, trying to become pregnant or breast feeing

          -  Evidence of alcohol or substance abuse in the last year

          -  History of caffeine withdrawal headache

          -  Consumes more than 275 mg of caffeine on daily basis from dietary and medication
             sources

          -  Taking propanolol
Clinical trial NCT00369278 (phase 3, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: enteric-coated mycophenolate sodium (ec-mps)
SMILES: COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
Eligibility criteria:

        Inclusion criteria

          1. Recipients of de novo cadaveric, living unrelated or living related kidney transplants

          2. Females capable of becoming pregnant must have a negative serum pregnancy test within
             7 days prior to or at baseline, and are required to practice an approved method of
             birth control for the duration of the study and for a period of 6 weeks following
             discontinuation of study medication, even where there has been a history of
             infertility.

          3. Patients who are willing and able to participate in the study and from whom written
             informed consent has been obtained.

        Exclusion criteria

          1. More than one previous renal transplantation

          2. Graft loss due to immunological reasons in the first year after transplantation (in
             case of secondary transplantation)

          3. Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any
             other organ, different from kidney

          4. Patients receiving a kidney from a non-heart beating donor

          5. Patients who are recipients of A-B-O incompatible transplants

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01448044 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: bms-790052 (ns5a replication complex inhibitor), placebo matching bms-790052, pegylated-interferon alfa 2a, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants chronically infected with HCV Genotype 4

          -  HCV RNA viral load of ≥ 10,000 IU/mL

          -  No previous exposure to an interferon formulation, RBV or HCV direct antiviral agent

          -  Results of a liver biopsy obtained within three years prior to enrollment to
             demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are
             permitted, however, and any prior biopsy is permitted

        Exclusion Criteria:

          -  Evidence of decompensated liver disease

          -  Documented or suspected Hepatocellular carcinoma (HCC)

          -  Positive for Hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus-1
             (HIV-1)/HIV-2 antibody at screening
Clinical trial NCT00536263 (phase 3, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: pegylated interferon alpha-2b, pegylated interferon alpha-2b, pegylated interferon alpha-2b
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with chronic hepatitis B:

               -  Serum hepatitis B surface antigen positive for at least 6 months

               -  Serum hepatitis B e antigen positive

               -  Serum negative for hepatitis B surface and e antibodies

               -  Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000
                  IU/mL

               -  Alanine aminotransferase (ALT) 2- to 10-times the upper limit of normal

          -  Compensated liver disease with certain minimum hematological and serum biochemical
             criteria

        Exclusion Criteria:

          -  Significant hepatic disease from an etiology other than hepatitis B virus

          -  Antiviral treatment for hepatitis within previous 6 months

          -  History of severe psychiatric disease, especially depression

          -  Unstable or significant cardiovascular disease

          -  Prolonged exposure to known hepatotoxins such as alcohol or drugs

          -  Any condition that could interfere with the subject participating in and completing
             the study
Clinical trial NCT01114204 (phase 3, status: completed)
Conditions: iron deficiency anemia
ICD codes: D50.9, D50.0, D50.8
Drugs: ferumoxytol, iron sucrose
SMILES: COC1=CC=CC=C1OCC(O)CO, O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Key Inclusion Criteria include:

          1. Males and females ≥18 years of age

          2. Participants with IDA defined as having:

               1. Hemoglobin <10.0 g/deciliter (dL)

               2. Transferrin saturation (TSAT) <20%

          3. Participants who have a history of unsatisfactory oral iron therapy or in whom oral
             iron cannot be used

          4. Female participants of childbearing potential who are sexually active must be on an
             effective method of birth control for at least 1 month prior to screening and agree to
             remain on birth control until completion of participation in the study

        Key Exclusion Criteria include:

          1. History of allergy to IV iron

          2. Allergy to two or more classes of drugs

          3. Participants on dialysis or with an estimated glomerular filtration rate <30
             mL/minute(min)/1.73 square meter (m^2)

          4. Female participants who are pregnant, intend to become pregnant, are breastfeeding,
             within 2 weeks postpartum, or have a positive serum/urine pregnancy test

          5. Hemoglobin ≤7.0 g/dL

          6. Serum ferritin >600 nanogram/mL
Clinical trial NCT00404794 (phase 3, status: completed)
Conditions: lupus nephritis, glomerulonephritis, membranous
ICD codes: B26.83, A51.44, N11.8, N11.9, N12, N04.2, N06.2, N00.2, N03.2, N05.2, N01.2, N02.2
Drugs: prednisolone and mycophenolate mofetil, prednisolone and tacrolimus
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  abnormal urine protein excretion and biopsy-proven membranous lupus nephritis